Tipifarnib Janssen Pharmaceutica

Current Opinion in Investigational Drugs

Volumn 3, Issue 2, 2002, Pages 313-319

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CP 609754; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GGTI 298; IRINOTECAN; L 778123; LONAFARNIB; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRAIN TUMOR; BREAST TUMOR; CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG FORMULATION; DRUG METABOLISM; DRUG SYNTHESIS; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DYSFUNCTION; LEUKEMIA; LUNG TUMOR; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PANCREAS TUMOR; PARESTHESIA; POLYDIPSIA; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; ATAXIA; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUGS, INVESTIGATIONAL; FARNESYLTRANSTRANSFERASE; HUMANS; NEOPLASMS; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036239527     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Inhibitors of protein farnesylation 1998
2. American Association for Cancer Research 1998: Promises and prospects for the next century
3. Current status and novel therapeutic approaches in advanced non-small cell lung cancer
4. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule
5. A phase I and pharmacokinetic study of farnesyltransferase inhibitor, R-115777, in advanced cancer
6. Synthesis and in vitro structure-activity relationships of imidazolyl-3-quinolinones as farnesyl protein transferase inhibitors (FTI)
7. Use of farnesyltransferase inhibitor R115777 in relapsed and refactory acute leukemias: Preliminary results of a phase I trial
8. A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced breast cancer
9. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor (FTI) R115777
10. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
11. Administration of biologically and clinically relevant doses of the farnesyltransferase inhibitor R115777 and gemcitabine are feasible without pharmacokinetic (PK) interactions: A phase I and PK study
12. Drug resistance to the farnesyltransferase inhibitor R-115777
13. A phase I, pharmacological and biological study of the farnesyltransferase inhibitor (FTI) R115777 and capecitabine in patients (pts) with advanced solid malignancies
14. Drug development pipeline: Johnson & Johnson
15. Effects of R115777, a farnesyltransferase inhibitor (FTI), on methylnitrosourea (MNU)-induced mammary cancers: Role of HaRas mutation
16. Preclinical antitumor and pharmacodynamic studies with the farnesyltransferase inhibitor (FTI) R115777
17. A phase I pharmacokinetic (PK) and biological study of the farensyltransferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid tumors
18. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the farnesyltransferase inhibitor (FTI) R115777 in Japanese patients with advanced non-hematological malignancies
19. A phase I trial of the farnesyltransferase inhibitor R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer
20. Enhanced myelosuppression of topotecan when combined with the farnesyltransferase inhibitor, R115777: A phase I and pharmacodynamic study
21. A phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (Herceptin) in patients with advanced cancer
22. Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor (FTI) R115777
23. Phase I trial of R115777, an oral farnesyltransferase (FTase) inhibitor, in children with refractory solid tumors and neurofibromatosis type I (NF1)
24. In brief: Janssen Zarnestra
25. Johnson & Johnson
26. Phase I and pharmacokinetic study of the orally administered farnesyltransferase inhibitor R115777 in patients with advanced solid tumors
27. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
28. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial
29. Unusual tight binding of R115777 to farnesyl protein transferase (FPT) allows for ex vivo measurement of FPT inhibition
30. Unexpected pharmacodynamics of the farnesyl protein transferase inhibitor
31. R115777 as farnesyl protein transferase inhibitor: Synthesis and SAR
32. Drug development pipeline: L-778123, RY-023 and RY-024
33. Mechanistic and pharmacogenomic analysis of Zarnestra (R115777) in acute myeloid leukemia
34. Clinical pharmacokinetics of Irinotecan given in combination with the farnesyltransferase inhibitor Zarnestra™
35. A phase I and pharmacokinetic (PK) study of the farnesyltransferase inhibitor, R115777 in combination with gemcitabine (Gem)
36. Inhibition of HDJ2 protein farnesylation in peripheral blood mononuclear cells as a pharmacodynamic endpoint in a phase I study of R115777 and gemcitabine
37. Current status of clinical trials of farnesyltransferase inhibitors
38. Healthcare: Medical Supplies and Devices. US Equity Research: Johnson & Johnson